Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Biomaterials. 2020 Feb 21;241:119906. doi: 10.1016/j.biomaterials.2020.119906

Fig. 6. FerA significantly improved hFIX expression and hemostasis in FIX−/− hemophilic mice.

Fig. 6.

1×1010 vg of pre-incubated scAAV8-hFIX vectors with DPBS or hDys-FerA domain were administered in FIX −/− mice via the retro-orbital injection. At 1, 2, 6, 8, 30, and 34 weeks after vector administration, plasma from FIX−/− mice were collected and isolated. (A) Total expressed hFIX protein in mouse plasma was determined by an ELISA assay. (B) Circulating functional hFIX activity was determined by an in vitro aPTT assay. The data of each group represent the average and SD from five mice. *** p < 0.001, **p <0.01, and *p < 0.05 compared to control mice with scAAV8/hFIX treatment only.